Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · IEX Real-Time Price · USD
3.860
+0.310 (8.73%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
105
Market Cap
2.71B USD
Revenue Chart
* The company reports in GBP currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
Dec 31, 2020 | 860.00K | - | - |
Dec 31, 2019 | - | - | - |
Jan 31, 2019 | 57.09M | 41.64M | 269.50% |
Jan 31, 2018 | 15.45M | 12.57M | 436.46% |
Jan 31, 2017 | 2.88M | - | - |
Jan 31, 2016 | 0 | - | - |
Jan 31, 2015 | 0 | - | - |
Jan 31, 2014 | 0 | - | - |
Jan 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
QuidelOrtho | 3.00B |
Neogen | 929.24M |
ACADIA Pharmaceuticals | 726.44M |
Certara | 354.34M |
MorphoSys AG | 264.75M |
Arrowhead Pharmaceuticals | 181.74M |
PROCEPT BioRobotics | 136.19M |
Arcellx | 110.32M |
SMMT News
- 3 days ago - Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 - Business Wire
- 16 days ago - Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors - Business Wire
- 18 days ago - Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum - Business Wire
- 18 days ago - Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor - Reuters
- 18 days ago - Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer - PRNewsWire
- 5 weeks ago - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 - Business Wire
- 6 weeks ago - Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 - Business Wire
- 6 weeks ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT - PRNewsWire